mVaccination Partnership

Partnership objectives

  1. Increase demand for immunization services & reduce non-compliance.
  2. Optimize the supply chain.
  3. Replace paper-based systems at point of service delivery.

This project aims to establish if mobile technology solutions could increase the proportion of children covered by vaccination. This project aims to establish if mobile technology solutions could increase the proportion of children covered by vaccination. Copyright GSK

What are the health needs and challenges?

Despite major advances in the funding and availability of vaccines worldwide, it is estimated that up to a fifth of children worldwide still do not receive basic vaccines. The proliferation of mobile phones in Africa offers an opportunity to create innovative and cost-effective ways to address barriers to universal vaccination.

Description of partnership activities and how they address needs and challenges

The initial focus of the partnership was a one-year pilot vaccination project in Mozambique, in collaboration with the Mozambique Ministry of Health. This project aims to establish if mobile technology solutions could increase the proportion of children covered by vaccination in Mozambique by an additional 5-10% through helping to encourage mothers to take up vaccination services, support health workers, improve record keeping, and enable better management of vaccine stock.

The partnership combines GSK healthcare and vaccine expertise with those of Vodafone, enabling mobile technology to help vaccinate children against common infectious diseases in Africa. Since the pilot programme for mVacciNation began in 2015, 52,871 children have been registered and 162,825 antigen vaccinations have been recorded on the system. The mVacciNation project is now being piloted in 50 facilities in Tanzania in partnership with Amref, with the objective of enrolling 74,713 infants by December 2016. The partnership also recently received approval to expand to Nigeria following a successful evaluation by the National Primary Healthcare Development Agency. This expansion will enable the project to reach thousands more children with life-saving vaccinations.

The project uses mobile technology to address barriers to increased take-up of vaccines in three key ways:

  • Mothers and caregivers are registered on the mVacciNation database and alerted by SMS to the availability and importance of lifesaving vaccinations against common childhood diseases. Mothers are able to schedule vaccination appointments by SMS and receive notifications of past and future vaccinations to ensure children complete the full schedule and become fully immunised.
  • Health workers are provided with smartphones with software allowing them to contact mothers, view and record vaccination histories, schedule vaccinations and report on follow-up visits.
  • Healthcare facilities are prompted to regularly report on crucial vaccination stock levels by SMS. This enables critical supply chain management and the availability of vaccines when and where they are needed, particularly in rural areas.

With funding from USAID and GAVI, the pilot in Mozambique is being independently evaluated by the J-PAL Africa research unit, based at the University of Cape Town, and the National Institute of Health of Mozambique.  The UCT team includes researchers from Yale University and Harvard School of Public Health. The evaluation will rigorously measure the impact of the program as well as assess its cost effectiveness, helping to inform scale-up decisions both across Mozambique and in other African countries.


Transforming vaccine coverage in Mozambique

Partnership information

Company(ies) GlaxoSmithKline

Partner(s) GAVI Alliance, Mozambique Ministry of Health, US Agency for International Development (USAID), Vodafone

Type of Partner(s) Government, Other Business, PDPs

Therapeutic Focus Vaccine-Preventable Diseases, Women and Children's Health, Non-Communicable Diseases

Disease(s) Cancer, Cervical Cancer, Children's Health, Hepatitis, Influenza, Measles, Meningitis C, Mumps, Paratyphoid fever, Pneumonia, Rotavirus, Rubella, Shigella, Typhoid Fever, Yellow Fever

Program Type(s) Health System Infrastructure - mHealth, Prevention Programs - Awareness & Outreach, Prevention Programs - Vaccines

Targeted Population(s) Children, Marginalised / Indigenous People, Mothers, People with low income

Region(s) Sub-Saharan Africa

Number of Countries 1

Country(ies) Mozambique

Start Date 2014

More information GSK Developing Countries Unit

Anticipated completion date Ongoing

« Innovative technologies – whether mobile devices, medicines or vaccines – are helping to transform global health. »

Sir Andrew Witty, CEO of GSK